biote Corp. — Form 10-Q
Filed August 7, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On June 8, 2026, BioTE Medical amended and restated executive agreements with Chairman Marc Beer (base $521,200 + 85% bonus target; 114,157 option grant) and Interim CEO Robert Peterson (base $658,800 + 72.5% bonus target; options = 0.56% of outstanding shares). Separately, Bret Christensen resigned as of June 8, 2026, joining the Board as non-employee director effective that date, eligible for director compensation per the Non-Employee Director Compensation Policy. All three agreements and the resignation effective-dated June 8, 2026.
Why this rating
Routine executive contract renewal with modest changes in compensation structure. No material change to board control, strategy, or financial position relative to $97.9M market cap. Director transition is administrative.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.